|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0468 | ED148507 | Eye Disease Only | No | Female | White | 69 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0682 | ED148561 | General Research Use | No | Female | White | 76 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2333 | ED149245 | Eye Disease Only | No | Female | White | 76 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2594 | ED149542 | General Research Use | No | Female | White | 79 | 6 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2958 | ED148957 | General Research Use | No | Female | White | 75 | 6 - AREDS AMD Severity Scale Step 6 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3196 | ED148814 | General Research Use | No | Male | White | 68 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3301 | ED148981 | General Research Use | No | Female | White | 76 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3503 | ED149125 | General Research Use | No | Female | White | 78 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3580 | ED148842 | General Research Use | No | Male | White | 62 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3657 | ED149806 | General Research Use | No | Female | White | 70 | 6 - AREDS AMD Severity Scale Step 6 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3676 | ED148808 | General Research Use | No | Female | White | 55 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_3863 | ED149685 | General Research Use | No | Female | White | 72 | 6 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0006 | ED149042 | General Research Use | No | Female | Black or African American | 62 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0519 | ED149482 | General Research Use | No | Female | White | 73 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0690 | ED148855 | Eye Disease Only | No | Female | White | 67 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0904 | ED148841 | General Research Use | No | Female | Black or African American | 67 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0969 | ED148812 | General Research Use | No | Female | Asian | 75 | 6 - AREDS AMD Severity Scale Step 6 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0978 | ED149823 | General Research Use | No | Female | White | 76 | 6 - AREDS AMD Severity Scale Step 6 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1223 | ED149702 | General Research Use | No | Male | White | 69 | 6 - AREDS AMD Severity Scale Step 6 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1419 | ED148819 | General Research Use | No | Female | White | 63 | 6 - AREDS AMD Severity Scale Step 4 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |